 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | delcetravir / Esfam Biotech
New P1 trial: A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects (clinicaltrials.gov) - Jul 12, 2022
P1, N=8, Not yet recruiting, Sponsor: Esfam Biotech Pty Ltd